International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

ABSTRACT:

Abstract

Early clinical experience with the use of chimeric antigen receptor (CAR) T-cell therapies for patients with acute myeloid leukemia (AML) has been beset by high rates of toxicities and low rates of response. We convened an international workshop with the goal of bringing investigators in the field of AML-directed CAR T-cell therapy together to facilitate discussion of challenges and to brainstorm potential solutions. Based on discussions at the workshop, it was evident that (1) treating and targeting AML with CAR T cells is associated with unique clinical challenges, and (2) variability in clinical trial design, definitions of toxicities, correlative data collection, and reporting methods hinders the field's ability to compare study outcomes and to develop best practices.

SUBMITTER: Naik S 

PROVIDER: S-EPMC12686697 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature